<DOC>
	<DOCNO>NCT02216422</DOCNO>
	<brief_summary>This multicenter study evaluate efficacy safety ombitasvir/paritaprevir/ritonavir dasabuvir co-administered ribavirin ( RBV ) 12 week treatment naïve pegylated-interferon alfa-2a alfa-2b ( pegIFN ) /RBV treatment-experienced , cirrhotic HCV genotype 1b-infected adult .</brief_summary>
	<brief_title>A Study Evaluate Chronic Hepatitis C Virus ( HCV ) Infection Cirrhotic Adults With Genotype 1b ( GT1b ) Infection</brief_title>
	<detailed_description>The primary objective study assess safety efficacy ( percentage participant achieve 12-week sustained virologic response ( SVR12 ) , [ HCV ribonucleic acid ( RNA ) &lt; low limit quantification ( LLOQ ) 12 week follow treatment ] ) co-formulated ombitasvir , paritaprevir , ritonavir ( ombitasvir/paritaprevir/r ) dasabuvir co-administered RBV 12 week HCV genotype 1b-infected adult participant compensate cirrhosis . The secondary objective study assess number percentage participant virologic failure treatment percentage participant relapse post-treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic hepatitis C , genotype 1binfection ( HCV RNA level great 1,000 IU/mL Screening ) Evidence liver cirrhosis confirm liver biopsy Fibroscan ChildPugh score less equal 6 Screening Participant never receive antiviral treatment ( include pegIFN/RBV ) hepatitis C infection ( treatmentnaïve participant ) documentation meet one defined category treatmentexperienced participant Absence hepatocellular carcinoma ( HCC ) indicate negative ultrasound , compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) perform within 3 month prior screen negative ultrasound screening . Females must postmenopausal , nonchild bear potential practicing specific form birth control Males must surgically sterile , agree practice 2 effective method birth control throughout course study . Positive screen hepatitis B Surface antigen antiHuman Immunodeficiency virus antibody Evidence current past ChildPugh B C classification Confirmed presence hepatocellular carcinoma Abnormal laboratory test Participant selfreported average drinking 2 drink per day current drinker Previous treatment direct act antiviral agent ( DAA ) contain regimen History solid organ transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 1b</keyword>
	<keyword>Interferon-Free</keyword>
</DOC>